drugset / Trial / NCT06208124
A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a FIH, ascending dose study to characterize the safety, tolerability, optimal dose and preliminary anti-tumor activity of IMM-6-415 in participants with advanced or metastatic solid tumors harboring RAS or RAF oncogenic mutations.
Timeline
- Start
- 2024-02-27
- Primary completion
- 2025-04-30
- Completion
- 2025-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMM-6-415 | Unknown | — | Oral |